Abstracts from CIPP XVI Meeting Libon june 2017.pdf
CIPP XVI ABSTRACTS
Figure 1. Correlations between sputum HMGB1 Levels and FEV1% in
infection during the first 2 years of life and confirmed asthma in
moderate (T0, T3, T6) and severe asthmatic children (T0, T3, T6).
Datasets collated by the Information Services Division (ISD) of the
NHS National Services Scotland were utilized. All live born infants
for the period 2000–2011 were identified and divided into two
cohorts based on whether or not they had a RSV-related
hospitalization during the first 2 years of life. Available data on
events, admissions, and hospital attendances during childhood (up to
16 years) were extracted.
Results and Discussion
A RSV cohort of 32,981 infants (4.45% of total) and a non-RSV
cohort of 707,437 infants were identified. In the RSV cohort, 9.41%
(3,102/32,981) of children had at least one hospitalization for
asthma during childhood compared to 2.24% (15,833/707,437) of
the non-RSV cohort (p < 0.001). 19.72% of all admissions for a
confirmed diagnosis of asthma came from the RSV cohort (7,167 vs.
29,182 in non-RSV cohort). The relative risk of asthma admission for
infants in the RSV cohort was 3.68 (95% CI 3.56–3.80, p < 0.001).
The admission rate for asthma was over 5 times higher in the RSV
Table 1. Clinical findings of asthmatic children and healthy controls
cohort compared to non-RSV cohort (217.31 per 1,000 infants vs.
41.25 per 1,000 infants, respectively). Use of any asthma medication
was also higher in the RSV cohort (26.8% vs. 14.4% in non-RSV
10.56 ± 0.32
11.07 ± 2.12
Severe RSV infection during infancy was significantly associated with
17.38 ± 0.23
the development of asthma during childhood, with the risk of a
Family history of
hospital admission for asthma being nearly 4 times higher in these
Serum Total IgE
162.67 ± 20.85
16.79 ± 7.31
125.02 ± 21.53
9.23 ± 3.71
66.35 ± 4.24
91.95 ± 3.27
children than in those with no history of RSV hospitalization. This
study provides further evidence of the long-term consequences of
severe RSV infection in infancy.
#A71 − Influence of Anti-inflammatory Treatment on
#A70 − The Impact of Severe Respiratory Syncytial Virus
(RSV) Infection during the First 2 Years of Life on
Development of Asthma.
Rodgers-Gray B 1, Coutts J 2, Morris C 3, Buchan S 1, Fullarton J 1,
Research, Strategen, LTD − Basingstoke, United Kingdom; 2National Health
Services, Royal Hospital for Children − Glasgow, United Kingdom; 3Info Services,
Information Services Division Scotland − Edinburgh, United Kingdom; 4Neonatology, Queen Alexandra Hospital − Portsmouth, United Kingdom
Exhaled Breath Temperature in Atopic and Nonatopic
Wojsyk − Banaszak I 1, Mikoś M 2, Szczepankiewicz A 3,
Sobkowiak P 2, Wielebska A 1, Kamńska A 2, Bręborowicz A 1.
Department of Pediatric Pulmonology, Allergy and Clinical Immunology, Poznan
University of Medical Sciences − Poznań, Poland; 2Department of Pneumonology,
Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences
− Poznań, Poland; 3Laboratory of Molecular and Cell Biology, Department of
Pneumonology, Pediatric Allergy and Clinical Immunology, Poznan University of
Medical Sciences − Poznań, Poland
Asthma is an inflammatory disease characterized by the heterogeneity
of its endotypes. Elevated temperature caused by increased blood
Respiratory syncytial virus (RSV) is the leading cause of lower-
flow is considered a typical feature of inflammation. Measurements of
respiratory tract infection (LRTI) in infants, with severe cases
exhaled breath temperature are being investigated as a potential
requiring hospitalization.(1) In addition to this acute burden, there is
marker of disease exacerbation.
increasing evidence to suggest a relationship between severe RSV
The aim of this study was to investigate the influence of inhaled
infection during infancy and recurrent wheeze or asthma.(2) This
glucocorticosteroids on exhaled breath temperature in atopic and
study aimed to identify and quantify any relationships between RSV
nonatopic asthmatic children.